Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 9/20 | 0.84 |
| ▸ | FPR2 | P25090 | 7/20 | 0.84 |
| ▸ | DNMT3B | Q9UBC3 | 4/20 | 0.84 |
| ▸ | GNMT | Q14749 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | GAPDH | P04406 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996534 | 1.00 | DNMT1 (0.84) | DNMT1FPR2DNMT3BGNMTDPP4 | |
| SCHEMBL3686527 | 1.00 | DNMT1 (0.84) | DNMT1FPR2DNMT3BGNMTDPP4 | |
| SCHEMBL3439727 | 1.00 | DNMT1 (0.84) | DNMT1FPR2DNMT3BGNMTDPP4 | |
| SCHEMBL23610066 | 0.91 | DNMT1 (1.00) | DNMT1FPR2DNMT3BDPP4MEN1 | |
| SCHEMBL23610113 | 0.87 | DNMT1 (1.00) | DNMT1FPR2DNMT3BDPP4MEN1 | |
| Adenosine SCHEMBL5150670 | 0.82 | ADORA3 (0.80) | DNMT1FPR2DNMT3BDPP4MEN1 | |
| SCHEMBL23624397 | 0.80 | DNMT1 (1.00) | DNMT1FPR2DNMT3BKMT2ADOT1L | |
| SCHEMBL23610153 | 0.80 | DNMT1 (1.00) | DNMT1FPR2DNMT3BKMT2ADOT1L | |
| SCHEMBL23610159 | 0.80 | DNMT1 (1.00) | DNMT1FPR2DNMT3BKMT2ADOT1L | |
| Deoxyadenosine SCHEMBL21001775 | 0.80 | DNMT1 (0.66) | DNMT1FPR2DNMT3BDPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505797-B2 | Conversion of alpha-hydroxyalkylated residues in biomolecules using methyltransferases | VILNIUS UNIVERSITY (LT) | 2016-11-29 | — | — | US | claimed |
| US-20150093752-A1 | Conversion of alpha-hydroxyalkylated residues in biomolecules using methyltransferases | VILNIUS UNIVERSITY (LT) | 2015-04-02 | — | — | US | claimed |
| US-20170067093-A1 | CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES | VILNIUS UNIVERSITY (LT) | 2017-03-09 | — | — | US | disclosed |
| US-9505797-B2 | Conversion of alpha-hydroxyalkylated residues in biomolecules using methyltransferases | VILNIUS UNIVERSITY (LT) | 2016-11-29 | — | — | US | disclosed |
| EP-2414527-B1 | CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INST (LT) | 2015-05-20 | — | — | EP | disclosed |
| US-20150093752-A1 | Conversion of alpha-hydroxyalkylated residues in biomolecules using methyltransferases | VILNIUS UNIVERSITY (LT) | 2015-04-02 | — | — | US | disclosed |
| US-8889352-B2 | Conversion of alpha-hydroxyalkylated residues in biomolecules using methyltransferases | VILNIUS UNIVERSITY (LT) | 2014-11-18 | — | — | US | disclosed |
| US-8822146-B2 | Derivatization of biomolecules by covalent coupling of non-cofactor compounds using methyltransferases | VILNIUS UNIVERSITY (LT) | 2014-09-02 | — | — | US | disclosed |
| EP-2414528-B1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | UNIV VILNIUS (LT) | 2014-05-07 | — | — | EP | disclosed |
| US-20120094280-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2012-04-19 | — | — | US | disclosed |
| US-20120088238-A1 | CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2012-04-12 | — | — | US | disclosed |
| EP-2414528-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | Biotechnologijos Institutas (LT) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414527-A1 | CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES | Biotechnologijos Institutas (LT) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010115847-A1 | CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115846-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088238-A1 | CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES | HNMT, SHMT1, BHMT | DNMT1 18/4885FPR2 2326/4885DNMT3B 69/4885 |
| US-20120094280-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | EZH1, DOHH, BHMT2 | DNMT1 9/4885FPR2 2003/4885DNMT3B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.